The coalition is led by Connecticut and began its antitrust litigation in 2016. Its third complaint covers about 80 generic drugs and names 26 corporate and 10 individual defendants. Earlier settlements with Sandoz, Glenmark, Lannett, Bausch, Apotex, Heritage, and Heritage's parent Emcure total $496.5 million. The states built their case on cooperating witnesses, a database of more than 20 million documents, and phone records.
The settlements were filed October 8, 2026, in the U.S. District Court for the District of Connecticut, where the parties are asking a judge for approval. The states are preparing for a first trial in Hartford, scheduled for February 2027. The settlement amounts for Ascend and Mayne remain subject to that court approval. Attorneys tracking these claims should check whether their clients bought covered drugs during the 2009–2019 window, since eligible purchasers can still file. The Connecticut trial could also shape how the remaining defendants respond, so the approval ruling and trial schedule are worth monitoring.